Vaccination as a modality to prevent Lyme disease. A status report.
Recombinant outer surface protein A (OspA) of Borrelia burgdorferi is a highly protective immunogen for prevention of Lyme disease in experimental animals. Humoral immunity is sufficient for protection. The principal mechanism of action is prevention of transmission of the spirochete from tick to host. A recombinant OspA vaccine has been licensed for use in dogs. The recent licensure of an OspA vaccine for humans resulted from a critical analysis of recently completed efficacy studies.
Wormser
G P
GP
Department of Medicine, New York Medical College, Valhalla, USA.
D000818:Animals; D000954:Antigens, Surface / Q000235:genetics / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D015748:Borrelia burgdorferi Group / Q000276:immunology*; D002986:Clinical Trials as Topic; D004285:Dogs; D006801:Humans; D008074:Lipoproteins; D008193:Lyme Disease / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*
D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein; D014614:Vaccines, Synthetic